NASDAQ:GERN Geron Q3 2025 Earnings Report $1.39 +0.01 (+0.72%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$1.41 +0.02 (+1.44%) As of 04:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Geron EPS ResultsActual EPSN/AConsensus EPS -$0.03Beat/MissN/AOne Year Ago EPSN/AGeron Revenue ResultsActual RevenueN/AExpected Revenue$55.24 millionBeat/MissN/AYoY Revenue GrowthN/AGeron Announcement DetailsQuarterQ3 2025Date11/6/2025TimeBefore Market OpensConference Call DateThursday, November 6, 2025Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Geron Earnings HeadlinesMaking Money In Biotech StocksOctober 9 at 6:03 PM | seekingalpha.comWhen Can We Expect A Profit From Geron Corporation (NASDAQ:GERN)?October 8 at 4:52 PM | finance.yahoo.comGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real opportunity isn’t in coins or bullion. In every major gold rally of the past 50 years, there’s been another investment that has delivered dramatically higher returns. | Weiss Ratings (Ad)Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 18, 2025 | globenewswire.comWhat Do Investors Think About Geron Corporation (GERN) Following Q2 Results?August 31, 2025 | finance.yahoo.comGeron to Participate in the 2025 Wells Fargo Healthcare ConferenceAugust 27, 2025 | businesswire.comSee More Geron Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Geron? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Geron and other key companies, straight to your email. Email Address About GeronGeron (NASDAQ:GERN) (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options. The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes. Imetelstat works by directly binding to the RNA template of telomerase, thereby blocking the enzyme’s activity and shortening telomeres in malignant cells. Preclinical studies have also explored potential applications of telomerase inhibition in various solid tumors. Founded in 1990 by researchers Elizabeth Blackburn, Carol Greider and Jack Szostak—who later received the Nobel Prize in Physiology or Medicine for their work on telomeres—Geron is headquartered in Foster City, California. The company has established collaborations and licensing agreements with academic institutions, contract research organizations and pharmaceutical partners to advance its clinical programs and expand its research capabilities. Under the leadership of CEO John A. Scarlett, Geron continues to build its infrastructure for late-stage clinical development. The company serves a global community of physicians, researchers and patients by conducting multi-center clinical trials across North America and Europe, with the goal of bringing telomerase-targeted therapies to market.View Geron ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings Fastenal (10/13/2025)Wells Fargo & Company (10/14/2025)Citigroup (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)The Goldman Sachs Group (10/14/2025)BlackRock (10/14/2025)ASML (10/15/2025)Kinder Morgan (10/15/2025)Bank of America (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
